This weeks #TenTweetNephJC makes us sad - does taking regular acetaminophen (paracetamol) cause hypertension?
Find out below in this rapid review of the Scottish trial, as we catch up on the #NephJC take on things 👇
What did I miss?
Observational trials suggest that acetaminophen increases BP, but (unlike NSAIDs) the widespread impression remains of a safe first-line therapy for chronic pain. The largest previous RCT had n=33.
✔️ Single-centre, double-blind, placebo-controlled, crossover study
✔️ 4g/day acetaminophen (the standard UK dose) 🆚 placebo
✔️ 2 weeks active or placebo ➡️ 2 weeks washout ➡️ 2 weeks on opposite treatment
✔️ Primary outcome = change in 24 hour ambulatory BP
1 Tweet Results
🔹103 patients
🔹 mean age 61
🔹 mean baseline BP 133/81, with 70% on at least one antihypertensive
Acetaminophen caused:
❗️Mean daytime systolic BP rise of 4.7 mmHg (p=<0.0001)
and
❗️Mean daytime diastolic BP rise of 1.6 mmHg (p=0.005)
A figure paints 1000 words
Give me something clever to say
“Given there’s a continuous relationship between BP & cardiovascular disease, & the use of paracetamol is so widespread, it is reasonable to hypothesise that the associated rise in BP could contribute to 1000s of additional CV events every year.”
Chat consensus?
1️⃣ Good trial, sad result
2️⃣ Can’t ignore impact of 4.7 mmHg rise in SBP on CV risk - it is a big deal
3️⃣ Our patients do need their pain managed: try non-pharmacological methods, but the ⬆️QoL from acetaminophen (or NSAIDs) can make side-effects worth the risk
Quote of the fortnight!
It’s again off topic and it’s again @captainchloride, but what a one tweet trial summary! Makes us feel bad for needing 10 tweets to do it….
✳️ Sometimes we have least data about the commonest meds - scary!
➡️ Up next - NephMadness chatter on 15/16 March, & then it’s a mechanistic study of diuretic resistance in CCF on 22/23 March. See you soon! pubmed.ncbi.nlm.nih.gov/34529781/
✳️ 10 tweets to catch-up on the most recent #NephJC ✳️
This week - when is the ideal time to start dialysis in progressive chronic kidney disease?
Later starts lower the burden on patients & use of healthcare resources, but what’s the trade-off?
What did I miss?
Previous observational studies analysing outcomes by eGFR at point of dialysis initiation suffered from immortal time bias, survivor bias, and lead time bias. This trial used clever new statistical methods to avoid these flaws!
Cochrane & KDIGO recommend children with steroid-sensitive nephrotic syndrome (SSNS) take low dose pred during upper resp tract infection (URTI) to ⬇️relapse risk, based on 4 small studies - does this hold up in a big RCT?
What did I miss?
We actually covered two studies this week in collaboration with @ipnajc but we can’t do both in #TenTweetNephJC! We’ll focus on the PREDNOS-2 trial.
Recent unsuccessful #RCT: STOP-IgA (immunosuppression+supportive care isn’t superior to supportive care alone) & TESTING (corticosteroids reduce risk of #ESRD but cause serious infections) were covered by @NephJC: nephjc.com/iga-nephropath…
and nephjc.com/news/2017/8/28… … (2/16)
Question for the #NephTwitter: What percentage of patients with IgA nephropathy develop #ESKD by 10 years? (3/16)
1/ #Tweetorial#NephJC#Hypernatremia Reviews and guidelines say to correct hypernatremia in adults by no more than 10 mmol/L per day. This is based on little hard data, has little support in literature and may be harmful nejm.org/doi/full/10.10…
2/ What rate do you target for the correction of chronic (>48 hours or present on admission) hypernatremia #NephJC
3/ The rapid lowering of serum sodium will lower the tonicity of the extracellular compartment. Water will then be osmotically drawn into relatively hypertonic intracellular compartment. This can cause cerebral edema and increased intracranial pressure. #NephJC